AUS
NZ
UK
CA
USA
IND
Highlights
- Underperformance in 2024: CSL shares fell 3% compared to a 10% rise in the ASX 200 index.
- Analyst Optimism: Bell Potter forecasts a 17% upside, targeting a price of $345.00.
- Growth Catalysts: Margin recovery and strong performance from CSL’s Behring division.
The CSL Ltd (ASX:CSL) share price has faced a challenging 2024, underperforming significantly compared to the broader market. While the S&P/ASX 200 index has surged over 10% year-to-date, excluding dividends, CSL shares have slipped approximately 3%. Adding to the disappointment, the biotech giant, once known for outperforming the market, has seen little movement in its share price since the pandemic began.
However, analysts believe that this period of stagnation may soon be over, with CSL on the brink of a renewed growth phase.
2024: A Year of Underperformance
CSL's underwhelming performance in 2024 is a stark contrast to its historical track record as a market leader. Since late 2019, the company’s share price has remained largely flat, leaving long-term investors questioning its ability to deliver value.
The lack of momentum in recent years has been attributed to several challenges, including pandemic-related disruptions and operational pressures. Despite these hurdles, analysts are optimistic about CSL's prospects, citing the company’s robust fundamentals and potential for a significant turnaround.
Analyst Predictions: A Bullish Outlook
In a recent report, Bell Potter analysts expressed confidence in CSL’s ability to bounce back. They highlight that the current market undervalues CSL, offering a compelling opportunity for investors. The broker assigns a "buy" rating to CSL, with a 12-month price target of $345.00—implying a potential upside of nearly 17% from its current price of $280.74.
Bell Potter notes that CSL is entering a "margin recovery phase," expected to drive above-market earnings growth in the coming years. The stock's current price-to-earnings (PE) ratio of 28x is below its 10-year average of 31x, reinforcing the undervaluation thesis. Additionally, the company is expected to reduce its leverage over the next few years, further solidifying its financial position.
Growth Drivers: Behring Division in Focus
One of CSL's key growth engines is its core Behring division, which specializes in plasma-derived therapies. Bell Potter anticipates this division will play a central role in delivering double-digit earnings growth. The margin recovery and operational efficiency within Behring are expected to propel CSL’s financial performance, aligning with the broader growth trajectory analysts predict.
Investment Potential
For investors, the predicted upside could translate into notable returns. A $5,000 investment in CSL at its current price could grow to approximately $5,800 by late 2025 if Bell Potter’s projections are accurate. This outlook positions CSL as an attractive option for those seeking long-term gains in the biotech sector.
